CochLear EBIT 2023-2024 | CHEOY

CochLear EBIT for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • CochLear 2024 EBIT was 0.312B, a 18.8% increase from 2023.
  • CochLear 2023 EBIT was 0.262B, a 9.64% decline from 2022.
  • CochLear 2022 EBIT was 0.29B, a 74.83% decline from 2021.

EBIT can be defined as earnings before interest and taxes.

CochLear EBIT 2023-2024 | CHEOY

  • CochLear 2024 EBIT was 0.312B, a 18.8% increase from 2023.
  • CochLear 2023 EBIT was 0.262B, a 9.64% decline from 2022.
  • CochLear 2022 EBIT was 0.29B, a 74.83% decline from 2021.

EBIT can be defined as earnings before interest and taxes.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$136B
CVS Health (CVS)$78.4B
Elevance Health (ELV)$62.6B
Cencora (COR)$56.8B
DiDi Global (DIDIY)$26.9B
Labcorp Holdings (LH)$20.4B
Natera (NTRA)$19B
BioMerieux (BMXMF)$16.9B
EUROFINS SCIENT (ERFSF)$14B
Solventum (SOLV)$12.7B
ICON (ICLR)$11.6B
Revvity (RVTY)$11B
Viatris (VTRS)$10.4B
Avantor (AVTR)$9.1B
Medpace Holdings (MEDP)$9B
Sonic Healthcare (SKHHY)$8.9B
HealthEquity (HQY)$8.4B
Caris Life Sciences,�Inc (CAI)$7.7B
Charles River Laboratories (CRL)$7.6B
Amplifon S.p.A (AMFPF)$5.4B
Bausch + Lomb (BLCO)$4.9B
BrightSpring Health Services (BTSG)$3.5B
Sotera Health (SHC)$3.1B
Surgery Partners (SGRY)$2.9B
Concentras Parent (CON)$2.5B
Organon (OGN)$2.5B
Alignment Healthcare (ALHC)$2.5B
GeneDx Holdings (WGS)$2.2B
Progyny (PGNY)$1.9B
PACS (PACS)$1.8B